Neurogene Inc. Current Liabilities
Neurogene Inc. (NGNE) had Current Liabilities of $21.50 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Liabilities, Current $21.50M.
- 2026-03-31: Liabilities, Current $18.87M.
- 2025-12-31: Liabilities, Current $16.41M.
- 2025-09-30: Liabilities, Current $14.71M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $21.50M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $18.87M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $16.41M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $14.71M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $15.44M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $14.09M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $15.16M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $15.80M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $13.07M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $11.82M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $22.97M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $5.21M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $4.88M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $7.16M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $6.65M 10-K · filed 2024-03-18 | $11.06M 10-K · filed 2023-03-20 |
| 2022-09-30 | $10.24M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $9.27M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $7.60M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $8.64M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $9.00M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $7.58M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $8.41M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $7.89M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $9.89M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $6.32M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $5.60M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $4.74M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $2.56M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $1.16M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $3.60M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $4.63M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $10.75M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $13.35M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $9.36M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $10.96M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $7.00M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $8.13M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $5.82M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $9.52M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $8.56M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $8.50M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $5.72M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $4.79M 10-K · filed 2017-03-09 | |
| 2015-09-30 | $3.86M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $3.98M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $4.97M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $5.20M 10-K · filed 2016-03-14 | $5.20M 10-K · filed 2015-03-16 |
| 2014-09-30 | $4.57M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $2.85M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $1.24M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $2.62M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |